Chronic Kidney Disease Diagnosis
Chronic Kidney Disease Diagnosis
The diagnosis rests on two measurements rather than on how a person feels, and each must be repeated before it counts. This page sets out what those two numbers measure and why one of them is missed far more often than it should be, what the additional tests are each for, how the cause is established, and the narrow set of circumstances in which a kidney biopsy genuinely changes the treatment.
Two numbers, twice, three months apart
The definition has a structure that is worth knowing, because it explains most of what follows. It needs an abnormality in filtration or in a marker of damage — and it needs that abnormality to have been present for at least three months, on at least two separate occasions. The repetition is not bureaucracy. It is what separates a chronic disease from a bad week.
Creatinine rises with dehydration, with a fever, with a large meat meal, and with a fortnight of anti-inflammatory painkillers. Albumin appears in the urine after heavy exercise, during a urinary infection, and with a fever. Any of these can produce a single abnormal result in a person whose kidneys are entirely healthy. What makes the finding chronic is that it persists when those things have resolved — which is exactly what the second measurement three months later establishes.
The two numbers also carry different information, which is why both are required rather than one. The filtration rate says how much work the kidneys are still doing. The albumin says how much damage is being done at the filter, which predicts both how fast the filtration rate will fall and how much cardiovascular risk attaches to the whole picture. A person can have one abnormal and not the other, and each of those combinations is a different situation with a different plan.
The filtration rate: eGFR
eGFR is an estimate of how much blood the kidneys filter per minute, calculated from a blood creatinine measurement and adjusted for age and sex. It is not a direct measurement — a true measurement requires an injection and timed collections — but it is standardised, cheap, and good enough to stage a disease and to follow a trend, which is what it is used for.
Three things about it are worth understanding. First, the same creatinine means different things in different people: muscle mass affects how much creatinine is produced, so a muscular young man and a frail elderly woman with identical kidney function will have quite different levels. The adjustment in the estimate handles the age and sex part, but not all of the muscle part, which is why very muscular or very underweight people occasionally need a more direct check.
Second, a second marker exists for exactly that reason. Cystatin C is a protein produced at a steady rate by all cells, unaffected by muscle mass, and measuring it alongside creatinine gives a filtration estimate that is more reliable in the people for whom creatinine is least reliable. It is not needed for everyone; it is needed where the creatinine picture and the clinical picture disagree.
Third — and this is the point that matters most clinically — the trend is more informative than any single value. A filtration rate of 55 that has been 90, 75 and 55 across three years describes an aggressive process. A filtration rate of 55 that has been 57, 56 and 55 across the same period describes a stable one. Same number, different disease, and only the sequence tells them apart.
The urine measurement: albumin-to-creatinine ratio
The urine test that matters is the albumin-to-creatinine ratio on a single sample, usually the first urine of the morning. It measures how much albumin is being lost, corrected for how concentrated that particular sample is — which is why a random sample works and a 24-hour collection, with all its inconvenience, is usually unnecessary.
The result is grouped into three categories, and the groups are not cosmetic. A1 is normal or near-normal. A2 is a moderate increase, which already means higher cardiovascular risk and a faster expected decline. A3 is a heavy leak, which accelerates loss of function and carries the greatest risk of both progression and cardiovascular events. The category travels with the filtration category wherever the disease is described: G3b A2 is not the same disease as G3b A3.
This is also the measurement most often missing from a records package. It is a single urine sample, it costs very little, and a large share of the international enquiries we receive come from patients whose creatinine has been followed for years while the albumin was never measured. When we review records before travel, an absent albumin result is the first gap we name.
Establishing what is actually causing it
Once the disease is confirmed, the next question is the cause, and the answer is not always the obvious one. Diabetes and hypertension are the commonest causes, but their presence does not prove they are responsible: a person with diabetes can also have an immune disease, and assuming the obvious is how a treatable condition is missed. The search is arranged by what each test can settle.
| Test | What it is looking for | When it earns its place |
|---|---|---|
| Kidney ultrasound | Size, scarring, symmetry, and whether urine is draining freely | Nearly always. Small scarred kidneys say chronic; an obstructed system says reversible; asymmetry points to a vascular or reflux problem |
| Immune blood tests | Autoantibodies, complement levels, immunoglobulin patterns — the fingerprints of glomerular and systemic immune disease | Where proteinuria is significant, where blood accompanies protein, or where the tempo is faster than diabetes or hypertension would explain |
| HbA1c and glucose history | How long glucose has been raised and how well it has been controlled | Always. The duration matters as much as the current value, because diabetic kidney disease is a product of years |
| Protein electrophoresis and free light chains | Abnormal proteins that deposit in the kidney and damage it | Where the pattern does not fit, particularly in older patients with heavy proteinuria |
| Kidney biopsy | Tissue read under light, immunofluorescence and electron microscopy | Where the result would change the treatment — the decision discussed below |
On biopsy specifically: the question is not whether it is safe enough but whether it is informative enough. Where the treatment would be the same either way, the risk earns nothing. Where the answer decides between immune suppression and supportive care, between one diagnosis and another with a different prognosis, or between treating and watching, it earns a great deal — and that is the standard on which it is recommended.
What a complete assessment contains
For international patients the assessment is deliberately built around records, because much of it already exists in any well-kept file. What we ask for is the creatinine or eGFR history with dates, the most recent urine albumin-to-creatinine ratio, any imaging reports, the blood pressure picture including home readings, the full medicines list including over-the-counter painkillers and supplements, and the history of the conditions that travel with kidney disease — diabetes, hypertension, heart disease, gout, autoimmune disease.
The written opinion that comes back covers four things: the stage on both axes, the likely cause and how confident that judgement is, which missing tests would change the plan, and whether the findings warrant assessment here at all. Where the answer is that the disease is already well managed and nothing would change, that is what the letter says. The review is free and it precedes any discussion of travel or payment, which is the ordering patients tell us matters most.